Related Experiment Video

Updated: Aug 9, 2026

An Ultrasonic Tool for Nerve Conduction Block in Diabetic Rat Models
10:27

An Ultrasonic Tool for Nerve Conduction Block in Diabetic Rat Models

Published on: October 20, 2017

Therapeutic effects of I(f) blockade: evidence and perspective

Jeffrey S Borer1

  • 1The Division of Cardiovascular Pathophysiology and The Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University, The New York-Presbyterian Hospital, Weill Cornell Medical Center, New York, NY, USA. canadad45@aol.com

Pharmacological Research
|April 20, 2006
PubMed

Insights

Ivabradine offers pure heart rate slowing for angina prevention by targeting the If current. This novel approach avoids side effects of other heart medications and is being studied for broader cardiovascular benefits.

Area of Science:

  • Cardiology
  • Pharmacology
  • Physiology

Background:

  • Heart rate slowing is a long-standing strategy for angina pectoris prevention and treatment.
  • Existing rate-slowing drugs (beta-blockers, calcium channel blockers) have non-specific effects, potentially causing adverse events.
  • Heart rate modulation is primarily controlled by the sinoatrial node's If current, a sodium-potassium mediated ion flow.

Purpose of the Study:

  • To review the efficacy of ivabradine, a novel If current inhibitor, for angina prevention.
  • To discuss the potential of ivabradine in treating other cardiovascular conditions.
  • To highlight the development and application of targeted heart rate modulation therapy.

Main Methods:

  • Review of clinical data and pharmacological studies on ivabradine.
  • Analysis of the mechanism of action of ivabradine on the If current.
  • Evaluation of existing literature on the therapeutic use of heart rate-slowing agents.

Main Results:

  • Ivabradine selectively inhibits the If current in the sinoatrial node, achieving pure heart rate slowing.
  • Demonstrated anti-anginal and anti-ischemic efficacy of ivabradine.
  • Ivabradine is under investigation for survival benefits in coronary artery disease and heart failure patients.

Conclusions:

  • Ivabradine represents a significant advancement in targeted cardiovascular therapy.
  • Selective If current inhibition offers a safer alternative for rate control in angina.
  • Further research is exploring ivabradine's role in managing heart failure and improving patient survival.

More Related Videos

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

Intracortical Inhibition Within the Primary Motor Cortex Can Be Modulated by Changing the Focus of Attention09:48

Intracortical Inhibition Within the Primary Motor Cortex Can Be Modulated by Changing the Focus of Attention

Published on: September 11, 2017

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Drugs Acting on Autonomic Ganglia: Blockers01:28

Drugs Acting on Autonomic Ganglia: Blockers

Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...